New and Emerging Agents in the Prevention and Treatment of Venous Thromboembolic Disease

This information was originally presented on September 15, 2012, at the NCCN 7th Annual Congress: Hematologic Malignancies™ held in New York, New York.

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Discuss factors that contribute to the risk of VTE and identify high-risk patients who may benefit most from thromboprophylaxis
  • Summarize the current standard of care for thromboprophylaxis in patients with cancer
  • Review clinical trial data from studies of new and emerging anticoagulation agents
Additional information
Supporters: 

Supported by educational grants from Genentech; Millennium: The Takeda Oncology Company; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc.; and sanofi-aventis U.S.

Course summary
Available credit: 
  • 0.75 Participation
  • 0.62 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician
Course opens: 
11/09/2012
Course expires: 
11/09/2013
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 7th Annual Congress: Hematologic Malignancies™

Michael B. Streiff, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Available Credit

  • 0.75 Participation
  • 0.62 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader for certificate viewing/printing